These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 28967901)

  • 1. Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy.
    Mett V; Komarova EA; Greene K; Bespalov I; Brackett C; Gillard B; Gleiberman AS; Toshkov IA; Aygün-Sunar S; Johnson C; Karasik E; Bapardekar-Nair M; Kurnasov OV; Osterman AL; Stanhope-Baker PS; Morrison C; Moser MT; Foster BA; Gudkov AV
    Oncogene; 2018 Jan; 37(4):439-449. PubMed ID: 28967901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human study of anticancer immunotherapy drug candidate mobilan: safety, pharmacokinetics and pharmacodynamics in prostate cancer patients.
    Eremina NV; Kazey VI; Mishugin SV; Leonenkov RV; Pushkar DY; Mett VL; Gudkov AV
    Oncotarget; 2020 Apr; 11(14):1273-1288. PubMed ID: 32292576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flagellin enhances tumor-specific CD8⁺ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model.
    Nguyen CT; Hong SH; Sin JI; Vu HV; Jeong K; Cho KO; Uematsu S; Akira S; Lee SE; Rhee JH
    Vaccine; 2013 Aug; 31(37):3879-87. PubMed ID: 23831323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist.
    Burdelya LG; Brackett CM; Kojouharov B; Gitlin II; Leonova KI; Gleiberman AS; Aygun-Sunar S; Veith J; Johnson C; Haderski GJ; Stanhope-Baker P; Allamaneni S; Skitzki J; Zeng M; Martsen E; Medvedev A; Scheblyakov D; Artemicheva NM; Logunov DY; Gintsburg AL; Naroditsky BS; Makarov SS; Gudkov AV
    Proc Natl Acad Sci U S A; 2013 May; 110(20):E1857-66. PubMed ID: 23630282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism.
    Yang H; Brackett CM; Morales-Tirado VM; Li Z; Zhang Q; Wilson MW; Benjamin C; Harris W; Waller EK; Gudkov AV; Burdelya LG; Grossniklaus HE
    Oncotarget; 2016 Jan; 7(3):2936-50. PubMed ID: 26655090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis.
    Brackett CM; Kojouharov B; Veith J; Greene KF; Burdelya LG; Gollnick SO; Abrams SI; Gudkov AV
    Proc Natl Acad Sci U S A; 2016 Feb; 113(7):E874-83. PubMed ID: 26831100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.
    Williams BJ; Bhatia S; Adams LK; Boling S; Carroll JL; Li XL; Rogers DL; Korokhov N; Kovesdi I; Pereboev AV; Curiel DT; Mathis JM
    PLoS One; 2012; 7(10):e46981. PubMed ID: 23056548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-step enhanced cancer immunotherapy with engineered
    Zheng JH; Nguyen VH; Jiang SN; Park SH; Tan W; Hong SH; Shin MG; Chung IJ; Hong Y; Bom HS; Choy HE; Lee SE; Rhee JH; Min JJ
    Sci Transl Med; 2017 Feb; 9(376):. PubMed ID: 28179508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects.
    Haderski GJ; Kandar BM; Brackett CM; Toshkov IM; Johnson CP; Paszkiewicz GM; Natarajan V; Gleiberman AS; Gudkov AV; Burdelya LG
    PLoS One; 2020; 15(2):e0227940. PubMed ID: 32027657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.
    Raja Gabaglia C; Diaz de Durana Y; Graham FL; Gauldie J; Sercarz EE; Braciak TA
    Cancer Res; 2007 Mar; 67(5):2290-7. PubMed ID: 17332360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
    Marshall NA; Galvin KC; Corcoran AM; Boon L; Higgs R; Mills KH
    Cancer Res; 2012 Feb; 72(3):581-91. PubMed ID: 22158905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Versatile prostate cancer treatment with inducible caspase and interleukin-12.
    Nikitina EY; Desai SA; Zhao X; Song W; Luo AZ; Gangula RD; Slawin KM; Spencer DM
    Cancer Res; 2005 May; 65(10):4309-19. PubMed ID: 15899823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A flagellin-derived toll-like receptor 5 agonist stimulates cytotoxic lymphocyte-mediated tumor immunity.
    Leigh ND; Bian G; Ding X; Liu H; Aygun-Sunar S; Burdelya LG; Gudkov AV; Cao X
    PLoS One; 2014; 9(1):e85587. PubMed ID: 24454895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer.
    Rhee SH; Im E; Pothoulakis C
    Gastroenterology; 2008 Aug; 135(2):518-28. PubMed ID: 18538140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flagellin acting via TLR5 is the major activator of key signaling pathways leading to NF-kappa B and proinflammatory gene program activation in intestinal epithelial cells.
    Tallant T; Deb A; Kar N; Lupica J; de Veer MJ; DiDonato JA
    BMC Microbiol; 2004 Aug; 4():33. PubMed ID: 15324458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pterostilbene, a novel natural plant conduct, inhibits high fat-induced atherosclerosis inflammation via NF-κB signaling pathway in Toll-like receptor 5 (TLR5) deficient mice.
    Zhang Y; Zhang Y
    Biomed Pharmacother; 2016 Jul; 81():345-355. PubMed ID: 27261612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity.
    Yu X; Guo C; Yi H; Qian J; Fisher PB; Subjeck JR; Wang XY
    Cancer Res; 2013 Apr; 73(7):2093-103. PubMed ID: 23333935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional characterization of chicken TLR5 reveals species-specific recognition of flagellin.
    Keestra AM; de Zoete MR; van Aubel RA; van Putten JP
    Mol Immunol; 2008 Mar; 45(5):1298-307. PubMed ID: 17964652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.